J0894 Decitabine injection
Also known as: Dacogen, decitabine
Decitabine injection, a hypomethylating cytidine analog for treatment of myelodysplastic syndrome and acute myeloid leukemia.
In Plain Language
Cancer chemotherapy medicine
Clinical Context
Used for treatment of myelodysplastic syndrome and acute myeloid leukemia in patients ineligible for intensive chemotherapy.
RVU Information
CPT J0894 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0894?
CPT J0894 (Decitabine injection) is a J Codes (Drugs) code. Decitabine injection, a hypomethylating cytidine analog for treatment of myelodysplastic syndrome and acute myeloid leukemia.
How is J0894 administered?
CPT J0894 is administered by a healthcare provider, typically via injection or infusion. Used for treatment of myelodysplastic syndrome and acute myeloid leukemia in patients ineligible for intensive chemotherapy. It is used by Oncology, Hematology, Internal Medicine.
When is CPT J0894 used?
Used for treatment of myelodysplastic syndrome and acute myeloid leukemia in patients ineligible for intensive chemotherapy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.